<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469479</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-180302</org_study_id>
    <nct_id>NCT03469479</nct_id>
  </id_info>
  <brief_title>Neoadjuvant HAIC for Huge Resectable HCC at BCLC A-B Stage</brief_title>
  <official_title>The Efficacy and Safety of Resection Plus Neoadjuvant Hepatic Arterial Infusion Chemotherapy Compared With Resection Alone in Patients With Huge BCLC A-B Stage Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of resection plus
      neoadjuvant hepatic arterial infusion chemotherapy (HAIC) compared with resection alone in
      patients with huge resectable hepatocellular carcinoma (HCC) BCLC A-B stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resection is the long-term therapeutic option for resectable hepatocellular carcinoma (HCC)
      patients. While a number of studies demonstrate poor effect and high relapse rate of
      resection for patients with huge hepatocellular carcinoma staged BCLC A/B. Our previous
      prospective study also revealed that neoadjuvant transarterial chemoembolization (TACE) seems
      to confer a survival benefit for resectable HCC. Recently, the results of our previous
      prospective study suggested that, compared with TACE, hepatic arterial infusion chemotherapy
      (HAIC) may improve the survivals for HCC with huge HCC.Thus, the investigators carried out
      this prospective randomized control to demonstrate the superiority of resection plus
      neoadjuvant HAIC over resection alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">March 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>Time to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>60 months</time_frame>
    <description>Time to recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of adverse events. Postoperative adverse events were graded based on CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Resection plus HAIC with FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin</description>
    <arm_group_label>Resection plus HAIC with FOLFOX</arm_group_label>
    <other_name>Hepatic Arterial Infusion Chemotherapy of FOLFOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic resection</intervention_name>
    <description>No cancer cells seen microscopically at the resection margin</description>
    <arm_group_label>Resection plus HAIC with FOLFOX</arm_group_label>
    <arm_group_label>Resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
             Association for the Study of the Liver (EASL), simultaneously staged as BCLC A or BCLC
             B based on Barcelona Clinic Liver Cancer staging system;

          -  The sum of diameters of all lesions longer than 10 cm with the maximum lesion longer
             than 7 cm

          -  Diagnosed as resectable with consensus by the panel of liver surgery experts;

          -  No past history of resection, radiofrequency ablation, TACE, TAI, chemotherapy or
             molecule-targeted treatment;

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only;

          -  Meet the following laboratory parameters:(a) Platelet count ≥ 75,000/μL; (b)Hemoglobin
             ≥ 8.5 g/dL;(c) Total bilirubin ≤ 30mmol/L;(d) Serum albumin

             ≥ 32 g/L;(e) ASL and AST ≤ 6 x upper limit of normal;(f) Serum creatinine

             ≤ 1.5 x upper limit of normal;(g) INR &gt; 2.3 or PT/APTT within normal limits; (h)
             Absolute neutrophil count (ANC) &gt;1,500/mm3;

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document. Exclusion Criteria;

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Known of serious heart disease which can nor endure the treatment such as cardiac
             ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Evidence of bleeding diathesis.

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Known central nervous system tumors including metastatic brain disease

          -  Poor compliance that can not comply with the course of treatment and follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Hepatobiliary Oncology of Sun Yat-sen University Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi, MD</last_name>
    <phone>(8620)-87343938</phone>
    <email>shiming@sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RongPing Guo, MD</last_name>
    <phone>(8620)-87342266</phone>
    <email>guorp@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523059</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wusheng Yu, MD</last_name>
      <phone>13827285010</phone>
      <email>yuwusheng1998@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, MD</last_name>
      <phone>8620-87343115</phone>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guosheng Tan, MD</last_name>
      <phone>13725254145</phone>
      <email>tgs1976@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Twelfth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanmin Zhou, MD</last_name>
      <phone>15521278919</phone>
      <email>13430288977@139.com</email>
    </contact>
    <investigator>
      <last_name>Jinghua Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiping Central Hospital</name>
      <address>
        <city>Kaiping</city>
        <state>Guangdong</state>
        <zip>529300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shijie Zhang, MD</last_name>
      <phone>13717287622</phone>
      <email>Shijie_9262511@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University Of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Wu, MD</last_name>
      <phone>13975486015</phone>
      <email>wxp19730806@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zheng, MD</last_name>
      <phone>13649265446</phone>
      <email>183421344@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming Shi</investigator_full_name>
    <investigator_title>Proffessor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant hepatic arterial infusion chemotherapy</keyword>
  <keyword>BCLC A/B</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

